Multibiomarker analysis in patients with acute myocardial infarction

BackgroundNovel biomarkers representing different pathobiological pathways and their role in patients with acute myocardial infarction (AMI) were studied. MethodsWe retrospectively analysed serum levels of soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR), heart-type fatty acid-binding protein (H-FABP) and plasma fetuin A in blood of patients with AMI (STEMI, n = 61; NSTEMI, n = 57) compared to controls with excluded coronary artery disease (n = 76). Furthermore, detailed correlation analysis was performed. ResultsCompared with controls, in patients with STEMI and NSTEMI higher levels expressed as median of sST2 in pg/mL (STEMI: 132109, NSTEMI: 119891, control: 5248; P < 0001), GDF-15 in pg/mL (STEMI: 8188, NSTEMI 6775, control 5486; P < 0001), suPAR in pg/mL (STEMI: 34611, NSTEMI: 34667, control: 24636; P < 0001), H-FABP in ng/mL (STEMI: 58, NSTEMI: 54, control: 00; P < 0001) and lower plasma fetuin A levels in g/mL (STEMI: 95, NSTEMI: 54, control: 1166; P < 0001) were detected. Correlation analysis found clinical and biochemical parameters such as ejection fraction, length of hospital stay, creatine kinase, NT-proBNP and hs Troponin T levels as well as inflammatory markers (CRP, leucocytes) to be significantly correlated with novel biomarkers. ConclusionPlasma levels of novel biomarkers were significantly elevated (sST2, GDF-15, H-FABP, suPAR) or inversely downregulated (fetuin A) in patients with AMI compared to a control group with excluded coronary artery disease. Significant correlations with various clinical parameters and standard biochemical markers were found.